JP2018505901A5 - - Google Patents

Download PDF

Info

Publication number
JP2018505901A5
JP2018505901A5 JP2017543816A JP2017543816A JP2018505901A5 JP 2018505901 A5 JP2018505901 A5 JP 2018505901A5 JP 2017543816 A JP2017543816 A JP 2017543816A JP 2017543816 A JP2017543816 A JP 2017543816A JP 2018505901 A5 JP2018505901 A5 JP 2018505901A5
Authority
JP
Japan
Prior art keywords
daily dose
day
schizophrenia
iloperidone
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017543816A
Other languages
English (en)
Japanese (ja)
Other versions
JP6885649B2 (ja
JP2018505901A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/018316 external-priority patent/WO2016134049A1/en
Publication of JP2018505901A publication Critical patent/JP2018505901A/ja
Publication of JP2018505901A5 publication Critical patent/JP2018505901A5/ja
Application granted granted Critical
Publication of JP6885649B2 publication Critical patent/JP6885649B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017543816A 2015-02-17 2016-02-17 統合失調症の治療のためのイロペリドン Active JP6885649B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562117173P 2015-02-17 2015-02-17
US62/117,173 2015-02-17
US201562172436P 2015-06-08 2015-06-08
US62/172,436 2015-06-08
PCT/US2016/018316 WO2016134049A1 (en) 2015-02-17 2016-02-17 Iloperidone for the treatment of schizophrenia

Publications (3)

Publication Number Publication Date
JP2018505901A JP2018505901A (ja) 2018-03-01
JP2018505901A5 true JP2018505901A5 (cg-RX-API-DMAC7.html) 2019-03-28
JP6885649B2 JP6885649B2 (ja) 2021-06-16

Family

ID=55532275

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017543816A Active JP6885649B2 (ja) 2015-02-17 2016-02-17 統合失調症の治療のためのイロペリドン

Country Status (9)

Country Link
US (2) US10441580B2 (cg-RX-API-DMAC7.html)
EP (1) EP3258935B1 (cg-RX-API-DMAC7.html)
JP (1) JP6885649B2 (cg-RX-API-DMAC7.html)
KR (1) KR102870956B1 (cg-RX-API-DMAC7.html)
CN (2) CN107249586A (cg-RX-API-DMAC7.html)
BR (1) BR112017017608A2 (cg-RX-API-DMAC7.html)
CA (1) CA2976383C (cg-RX-API-DMAC7.html)
ES (1) ES2870498T3 (cg-RX-API-DMAC7.html)
WO (1) WO2016134049A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11214827B2 (en) * 2018-08-30 2022-01-04 Vanda Pharmaceuticals Inc. Genetic markers for enhancing efficacy of antipsychotic treatment with iloperidone
IL321015A (en) * 2022-12-19 2025-07-01 Vanda Pharmaceuticals Inc ILOPERIDONE dosing regimen for the treatment of bipolar I disorder and schizophrenia
CN121218989A (zh) 2023-06-02 2025-12-26 万达制药公司 使用伊潘立酮的治疗方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2398434T3 (es) 2001-08-31 2013-03-19 Novartis Ag Isómeros ópticos de un metabolito de iloperidona
EP1441727B1 (en) 2001-10-30 2010-12-29 Novartis AG Depot formulations of iloperidone and a star polymer
GB0216416D0 (en) 2002-07-15 2002-08-21 Novartis Ag Organic compounds
CA2582022C (en) * 2004-09-30 2021-05-18 Vanda Pharmaceuticals, Inc. Methods for the administration of iloperidone
US20100063093A1 (en) 2007-03-28 2010-03-11 Curt Wolfgang Methods for the administration of iloperidone
US9328387B2 (en) * 2007-09-10 2016-05-03 Vanda Pharmaceuticals, Inc. Antipsychotic treatment based on SNP genotype
KR102318070B1 (ko) * 2007-12-19 2021-10-27 얀센 파마슈티카 엔.브이. 장기 작용성 주사가능 팔리페리돈 에스테르와 관련된 투여 요법
EP2430183B1 (en) * 2009-05-15 2014-12-17 Vanda Pharmaceuticals Inc. Antipsychotic treatment based on drd2 or ankk1 snp genotype
US20140350029A1 (en) 2011-12-02 2014-11-27 Dainippon Sumitomo Pharma Co., Ltd. Lurasidone novel dosage regimens and use thereof for the treatment, prevention, and/or management of at least one cns disorder
BR112014022687A8 (pt) 2012-03-14 2021-07-06 Vanda Pharmaceuticals Inc uso de uma quantidade eficaz de r-p88 ou um sal farmaceuticamente aceitável do mesmo, ou um éster do mesmo ou um sal farmaceuticamente aceitável de um éster do mesmo, composição farmacêutica, r-p88 ou um sal farmaceuticamente aceitável do mesmo, ou um éster do mesmo ou um sal farmaceuticamente aceitável de um éster do mesmo
IL294306B2 (en) * 2012-08-21 2024-01-01 Sage Therapeutics Inc Methods of treating epilepsy or status epilepticus

Similar Documents

Publication Publication Date Title
JP2012193216A5 (cg-RX-API-DMAC7.html)
JP2015512406A5 (cg-RX-API-DMAC7.html)
JP2020023574A5 (ja) 近視予防、治療又は抑制用点眼剤、及び、小胞体ストレス抑制用点眼剤
JP2017531033A5 (cg-RX-API-DMAC7.html)
JP2017506624A5 (cg-RX-API-DMAC7.html)
JP2010523587A5 (cg-RX-API-DMAC7.html)
JP2015517488A5 (cg-RX-API-DMAC7.html)
JP2016147915A5 (cg-RX-API-DMAC7.html)
JP2018529742A5 (cg-RX-API-DMAC7.html)
RU2017116740A (ru) Комбинации для лечения рассеянного склероза
JP2018530578A5 (cg-RX-API-DMAC7.html)
JP2017503014A5 (cg-RX-API-DMAC7.html)
JP2015510916A5 (cg-RX-API-DMAC7.html)
JP2014520856A5 (cg-RX-API-DMAC7.html)
JP2019535760A5 (ja) ガボキサドールを用いた注意欠陥多動性障害(adhd)の治療方法
JP2018529666A5 (cg-RX-API-DMAC7.html)
JP2017105859A5 (cg-RX-API-DMAC7.html)
JP2018521007A5 (cg-RX-API-DMAC7.html)
JP2014507475A5 (cg-RX-API-DMAC7.html)
ZA202000028B (en) Use of vibegron to treat overactive bladder
JP2017526693A5 (cg-RX-API-DMAC7.html)
JP2018505901A5 (cg-RX-API-DMAC7.html)
JP2020533296A5 (cg-RX-API-DMAC7.html)
RU2018146504A (ru) Лечение внутрипеченочных холестатических заболеваний
JP2016505050A5 (cg-RX-API-DMAC7.html)